CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Shares withheld for taxes EVP of R&D gave up 8,464 shares (to pay taxes)
- 8-K Event Other events
- 4 Shares withheld for taxes EVP of R&D gave up 8,968 shares (to pay taxes)
- 8-K Event Other events
- 4 Open-market sale Director sold 15,000 shares at an average $16.75 ($251,250)
- 4 Open-market sale Director sold 15,000 shares at an average $16.75 ($251,250)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.97 ($23,940)
- SC TO-I/A Deal Tender Offer Statement by Issuer
- 4 Grant or award Director acquired 35,328 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- SC TO-I/A Deal Tender Offer Statement by Issuer
- 8-K Event Executive or director change
- 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.44 ($22,880)
- 4 Open-market sale Director sold 10,000 shares at $11.76 ($117,600)
- 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.18 ($22,360)
- SC TO-I Deal Tender Offer Statement by Issuer
Page 16 of 30 · 587 filings